Your GLP-1 Was Denied. Here's How to Appeal

If your GLP-1 was denied, you have a ladder to climb, and most people never take the first step. Get the denial in writing with the specific criteria the plan used. Ask your prescriber to request a peer-to-peer review — a direct call with the plan's medical director, often the fastest reversal. If that fails, file an internal appeal (generally within 180 days of the denial notice). If the plan still says no, most US plans must give you an independent external review, and the reviewer's decision is legally binding on the insurer.

The numbers are lopsided in a way that should make you angry, and then make you act. In 2024, insurers on HealthCare.gov denied about 19% of in-network claims — roughly 85 million of them. Consumers appealed at least 262,982, an appeal rate of under 1%. Of the appeals filed, insurers overturned their own decision about 34% of the time. And of the internal appeals the plan upheld, only about 4% went on to external review (KFF analysis of CMS transparency data).

An honest note on the last rung: KFF says the overturn rate for those federal Marketplace external appeals cannot be calculated from the public data, because CMS suppresses small values. So nobody can tell you the exact odds there. What we do have is a 2025 Health Affairs study of independent medical review in four states (2019–23): almost half of the plan denials that reached an independent reviewer were overturned, averaging about 45% and ranging from roughly 21% in some states to over 70% in others. That is the best evidence available, and it is not a rounding error.

Translation: the system quietly relies on you giving up. Don't.

First, find out what kind of "no" you actually got

This is the single most important step, and most articles skip it. There are two very different denials, and they need two different responses.

If it's an exclusion, filing may still be worth it — some plans cover the same molecule for a different approved indication, and your clinical picture may qualify you there. But the realistic lever is often your employer's HR or benefits team, who choose the drug list, not the insurer's appeals department. If it's a medical-necessity denial, keep reading: this is the ladder built for you.

Step 0: Demand the denial in writing — and the criteria

A phone call from the pharmacy saying "insurance rejected it" is not a denial. A denial is an adverse benefit determination, and federal rules require the notice to tell you the specific reason for the denial, the plan provision or clinical criteria it relied on, and how to appeal, including your deadlines (HealthCare.gov). You are also entitled, on request and free of charge, to the internal rule, guideline or protocol used to decide your case.

Ask for it exactly like this, in writing, to the number on your insurance card:

"Please send me the written adverse benefit determination for [drug name], including the specific clinical criteria or coverage policy relied on, and the deadline and instructions for internal appeal and external review."

You cannot rebut criteria you have never been shown. An appeal that argues with a rule the writer never read is a letter of feelings, and plans dispose of those for a living. An appeal that quotes the plan's own criterion and answers it with a chart note is a different animal entirely.

Step 1: Peer-to-peer — the step people skip

A peer-to-peer (P2P) is a scheduled phone conversation between your prescriber and the plan's medical director. Your clinician requests it; you cannot do it yourself. The window is short and plan-specific — your denial letter, or your prescriber's copy of the plan's provider manual, states it. Treat it as urgent and ask the same day the denial arrives.

It is frequently the highest-yield step, because a great many denials are not clinical disagreements at all: they are missing data. The reviewer never saw the A1c, the sleep-apnea study, the documented history of prior attempts, the reason a step-therapy drug was inappropriate for you. A five-minute call fixes what a form could not.

What you can do to make the call land: give your prescriber's office a single, dated summary — your weight history, the specific comorbidities in the plan's own criteria language, what you have already tried and what happened, and any drugs you cannot take and why. Do not exaggerate anything, and never let anyone, including yourself, describe your history inaccurately to an insurer. Aside from being wrong, it destroys your credibility at exactly the rung where credibility is the whole case.

Step 2: The internal appeal (the plan reviews itself)

You generally have 180 days from receiving the denial to file an internal appeal, and the plan must have someone who was not involved in the original decision look again.

How to structure the letter (this is a structure, not a template, and not legal advice)

We are deliberately not handing you a fill-in-the-blanks letter. A form letter with your name dropped in reads exactly like what it is, and the facts that win are yours, not ours. Every appeal that works does the same four things.

1. Identify the claim precisely. Member ID, claim or reference number from the denial, drug and strength as prescribed, prescriber name and NPI, date of denial.
2. Quote the plan's own stated reason back to it. Not "you denied me unfairly" — "the denial states criterion 2(b) was not met."
3. Answer that criterion with evidence, point by point. Attach chart notes, lab values, prior-therapy history with dates and outcomes, and documentation of any contraindication. Every claim you make should be traceable to a document you enclosed.
4. Ask for a specific outcome and preserve your rights. State what you want approved, ask for a peer-to-peer if one has not happened, and state that you intend to pursue external review if the denial is upheld.

Add a short paragraph in your own voice about what the denial costs you in daily life. It is not decorative — reviewers are human, and it is the one thing a claims file cannot show.

Step 3: External review — your legal right, and the plan must obey it

This is the rung insurers depend on you not knowing about. In KFF's consumer survey, only about 40% of insured adults believed they had a right to appeal to an independent expert or government agency; about half were simply unsure. Most people do have that right.

Under the Affordable Care Act, if your non-grandfathered plan upholds its denial, you can take the case to an independent third party — an outside reviewer with no financial stake in the answer. Key facts, per HealthCare.gov and CMS (checked July 13, 2026):

• You have four months from the final internal denial to file.
• Standard reviews are decided within 45 days; expedited reviews for urgent situations within 72 hours.
• Your insurer is required by law to accept the decision. It is not advisory.
• It is free in the HHS-administered federal process. Where a state process charges a filing fee, federal standards cap it at $25 per review.
• It covers denials involving medical judgment, and denials calling a treatment experimental or investigational — which is what a GLP-1 medical-necessity denial is.

Your denial notice must tell you which process applies to you: your state's external review process, or the HHS-administered federal one. In the federal process, requests go through MAXIMUS Federal Services on behalf of HHS — you can file online at externalappeal.cms.gov or call 1-888-866-6205 to request the form.

Two honest caveats. Grandfathered plans, short-term plans and some other arrangements sit outside these protections. And a pure benefit exclusion — "this plan does not cover weight-loss drugs" — is a contract question, not a medical judgment, so external review may not reach it. Your plan documents decide that, and we cannot know your plan. The question to ask the number on your card: "Is my denial eligible for external review, and under which process — state or HHS-administered federal?"

If the appeal fails: the fallbacks, and their real limits

These change constantly. Everything below was checked on the manufacturers' own pages on July 13, 2026. Re-check before you rely on any of it — a price that was true when this was written can be gone by the time you read it.

Note what these fallbacks are not. They are not insurance. They generally do not count toward your deductible or out-of-pocket maximum. And they are promotions a manufacturer can withdraw, which is a real risk for a medication whose benefits reverse when you stop taking it. That is a reason to keep pushing the appeal even while you pay cash — not a reason to stop treatment on your own.

Compounded GLP-1s: what the record actually says

When cash prices bite, compounded semaglutide and tirzepatide start showing up in your ads. Here is the record, plainly.

Compounded GLP-1s are not FDA-approved. The FDA has not reviewed them for safety, effectiveness or manufacturing quality, and they do not carry an approved label. The legal opening that allowed mass compounding was the drug shortage: the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the enforcement grace periods ended during 2025. On May 1, 2026 the FDA published a Federal Register proposal to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substance; the comment period closed on June 30, 2026 (FDA).

The safety record is not abstract. The FDA has logged hundreds of adverse-event reports involving compounded semaglutide and compounded tirzepatide, and a recurring pattern is dosing errors: patients supplied with a multi-dose vial and a syringe, converting between milligrams and "units" or milliliters, and drawing up several times the intended dose — with cases severe enough to require hospitalization. A pre-filled pen makes that mistake hard. A vial and a syringe make it easy.

Whether any of that changes what is right for you is a decision to make with a clinician who knows your history — not with a website, including ours.

Talk to your prescriber — and what to ask

Get in touch with your prescriber's office as soon as a denial arrives, not weeks later; the peer-to-peer window is short. Call sooner if you are rationing, splitting or skipping doses to stretch a supply, or considering stopping abruptly because of cost.

Do not self-adjust your dose, and do not double up after a missed dose. Your prescriber sets your dose. The FDA-approved label publishes the approved dose schedule as public fact, but a label is a reference document, not an instruction to you — a dose is set by a clinician who knows your history, never by a table and never by a budget.

Bring these questions:

• "Will you request a peer-to-peer review with the plan's medical director, and by when?"
• "Which of the plan's stated criteria does my chart already document, and what's missing?"
• "If I can't get this covered, what is the clinically reasonable next option for me?"

Seek urgent medical advice for symptoms that have nothing to do with coverage: severe or persistent abdominal pain, especially radiating to the back; persistent vomiting or signs of dehydration; or sudden vision changes.

Where to go next

To understand what you're arguing for, start with how GLP-1 medications actually work and the differences between Zepbound and Wegovy and Wegovy and Ozempic — plans often cover one and not another, and that distinction can be the whole appeal. If coverage is out of reach for now, the honest alternatives are worth knowing. Our cost and coverage estimator can help you map what you'd actually pay, and our weight and metabolism hub has the rest.

If you're considering a telehealth route, judge it like a clinic, not an ad: does a licensed clinician in your state actually evaluate you, do they dispense FDA-approved product from a licensed pharmacy, will they write the prior authorization and do a peer-to-peer on your behalf, and can you reach a human when something goes wrong? A service that won't fight your denial is selling you convenience, not care. We don't recommend any specific provider, and you should be suspicious of anyone who does.

Disclosure: VidaBeacon may earn a commission if you use some of the links on this site. That never affects what we write here — no manufacturer, insurer or telehealth company paid for or reviewed this page, and we do not recommend any specific provider.

This article is information, not medical or legal advice. Coverage rules, prices and manufacturer programs change frequently; verify current terms with your plan and the manufacturer before acting.